Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials

European Journal of Clinical Nutrition volume 73, pages 345–355 (2019)Cite this article

Subjects

Abstract

Background

Resveratrol as a polyphenolic compound might be able to reduce inflammatory mediators. Change in inflammatory state is identified by the measurement of inflammatory mediators such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP). The objective of this study is to conduct a systematic review and meta-analysis on randomized controlled trials that assessed the effect of resveratrol on concentration of serum inflammatory mediators.

Method

Systematic search was performed up to October 2017 using ISI web of science, PubMed, Scopus, EMBASE, and Google scholar. Weighted mean difference was estimated either by subtracting baseline values from post-intervention value or as the post-intervention values. Fixed effect model was applied to analyze data where heterogeneity was <25%; otherwise, random effects models were applied. The protocol was registered with PROSPERO (No. CRD42018085098).

Results

The meta-analysis and systematic review considered 15 trials, involving 658 adults aged 18–75 years. Resveratrol significantly reduced serum CRP levels (WMD = −0.54; 95% CI: −0.78, −0.30; I2 = 77.7%; P < 0.0001), but it had no significant effect on serum IL-6 (WMD = −0.06; 95% CI: −0.27, 0.14; I2 = 62.0%; P = 0.005) and TNF-α levels (WMD = −0.20; 95% CI: −0.55, 0.16; I2 = 87.2%; P < 0.0001). Resveratrol intake reduced TNF-α in young subjects (WMD = −0.34; 95% CI: −0.57, −0.12; I2 = 60.5%; P = 0.038) and obese individuals (WMD = −1.52; 95% CI: −2.87, −0.16; I2 = 74.1%; P = 0.004).

Conclusion

The analysis indicated possible decreasing effect of resveratrol on CRP, but it might not be able to change IL-6 and TNF-α concentrations. More studies, separately on males and females with obesity, and varied age, are necessary.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105:141–50.

    Article  CAS  Google Scholar 

  2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.

    Article  CAS  Google Scholar 

  3. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8(Suppl 2):S3.

    Article  Google Scholar 

  4. Ruan H, Lodish HF. Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003;14:447–55.

    Article  CAS  Google Scholar 

  5. Silva D, Pais de Lacerda A. [High-sensitivity C-reactive protein as a biomarker of risk in coronary artery disease]. Rev Port Cardiol. 2012;31:733–45.

    Article  Google Scholar 

  6. Casas-Agustench P, Bullo M, Salas-Salvado J. Nuts, inflammation and insulin resistance. Asia Pac J Clin Nutr. 2010;19:124–30.

    CAS  PubMed  Google Scholar 

  7. Azimi P, Ghiasvand R, Feizi A, Hosseinzadeh J, Bahreynian M, Hariri M, et al. Effect of cinnamon, cardamom, saffron and ginger consumption on blood pressure and a marker of endothelial function in patients with type 2 diabetes mellitus: a randomized controlled clinical trial. Blood Press. 2016;25:133–40.

    Article  CAS  Google Scholar 

  8. Hariri M, Salehi R, Feizi A, Mirlohi M, Ghiasvand R, Habibi N. A randomized, double-blind, placebo-controlled, clinical trial on probiotic soy milk and soy milk: effects on epigenetics and oxidative stress in patients with type II diabetes. Genes Nutr. 2015;10:52.

    Article  Google Scholar 

  9. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res. 2009;53:115–28.

    Article  CAS  Google Scholar 

  10. Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72:1439–52.

    Article  CAS  Google Scholar 

  11. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006;5:493–506.

    Article  CAS  Google Scholar 

  12. Orallo F. Trans-resveratrol: a magical elixir of eternal youth? Curr Med Chem. 2008;15:1887–98.

    Article  CAS  Google Scholar 

  13. Xiao J, Song J, Hodara V, Ford A, Wang XL, Shi Q, et al. Protective effects of resveratrol on TNF-alpha-induced endothelial cytotoxicity in baboon femoral arterial endothelial cells. J Diabetes Res. 2013;2013:185172.

    Article  Google Scholar 

  14. Smoliga JM, Baur JA, Hausenblas HA. Resveratrol and health—a comprehensive review of human clinical trials. Mol Nutr Food Res. 2011;55:1129–41.

    Article  CAS  Google Scholar 

  15. Cui X, Jin Y, Hofseth AB, Pena E, Habiger J, Chumanevich A, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila). 2010;3:549–59.

    Article  CAS  Google Scholar 

  16. Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013;27:37–48.

    Article  CAS  Google Scholar 

  17. Tome-Carneiro J, Larrosa M, Yanez-Gascon MJ, Davalos A, Gil-Zamorano J, Gonzalvez M, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69–82.

    Article  CAS  Google Scholar 

  18. Esposito E, Cuzzocrea S. TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem. 2009;16:3152–67.

    Article  CAS  Google Scholar 

  19. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805–12.

    Article  CAS  Google Scholar 

  20. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.

    Article  CAS  Google Scholar 

  21. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. London: The Cochrane Collaboration; 2011.

  22. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.

    Article  Google Scholar 

  23. DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45(Pt A):139–45.

    Article  Google Scholar 

  24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

    Article  Google Scholar 

  25. Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, et al. Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res. 2016;111:896–905.

    Article  CAS  Google Scholar 

  26. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O’Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092–103.e1-6.

    Article  CAS  Google Scholar 

  27. Kjaer TN, Ornstrup MJ, Poulsen MM, Stodkilde-Jorgensen H, Jessen N, Jorgensen JOL, et al. No beneficial effects of resveratrol on the metabolic syndrome: a randomized placebo-controlled clinical trial. J Clin Endocrinol Metab. 2017;102:1642–51.

    Article  Google Scholar 

  28. Macedo RC, Vieira A, Marin DP, Otton R. Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test—a placebo-controlled, double blind study. Chem Biol Interact. 2015;227:89–95.

    Article  CAS  Google Scholar 

  29. Olesen J, Gliemann L, Bienso R, Schmidt J, Hellsten Y, Pilegaard H. Exercise training, but not resveratrol, improves metabolic and inflammatory status in skeletal muscle of aged men. J Physiol. 2014;592:1873–86.

    Article  CAS  Google Scholar 

  30. Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol. 2012;110:356–63.

    Article  CAS  Google Scholar 

  31. Zahedi HS, Jazayeri S, Ghiasvand R, Djalali M, Eshraghian MR. Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. Int J Prev Med. 2013;4(Suppl 1):S1–4.

    PubMed  PubMed Central  Google Scholar 

  32. Bashmakov YK, Assaad-Khalil SH, Abou Seif M, Udumyan R, Megallaa M, Rohoma KH, et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014;2014:816307.

    Article  Google Scholar 

  33. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli F, Villois P, et al. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr Med Chem. 2013;20:1323–31.

    Article  CAS  Google Scholar 

  34. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K, Patnaik P, Marumganti A, et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab. 2010;95:E1–8.

    Article  Google Scholar 

  35. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–64.

    Article  CAS  Google Scholar 

  36. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50:179–87.

    CAS  PubMed  Google Scholar 

  37. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95.

    Article  CAS  Google Scholar 

  38. Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55.

    Article  Google Scholar 

  39. Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016;17:1329–40.

    Article  CAS  Google Scholar 

  40. Ghanem FA, Movahed A. Inflammation in high blood pressure: a clinician perspective. J Am Soc Hypertens. 2007;1:113–9.

    Article  Google Scholar 

  41. Zhu X, Wu C, Qiu S, Yuan X, Li L. Effects of resveratrol on glucose control and insulin sensitivity in subjects with type 2 diabetes: systematic review and meta-analysis. Nutr Metab (Lond). 2017;14:60.

    Article  Google Scholar 

  42. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793–801.

    Article  CAS  Google Scholar 

  43. Wu T, Dorn JP, Donahue RP, Sempos CT, Trevisan M. Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988–94. Am J Epidemiol. 2002;155:65–71.

    Article  Google Scholar 

  44. Haghighatdoost F, Hariri M. Effect of resveratrol on lipid profile: an updated systematic review and meta-analysis on randomized clinical trials. Pharmacol Res. 2018;129:141–50.

    Article  CAS  Google Scholar 

  45. Tome-Carneiro J, Larrosa M, Gonzalez-Sarrias A, Tomas-Barberan FA, Garcia-Conesa MT, Espin JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19:6064–93.

    Article  CAS  Google Scholar 

  46. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011;14:612–22.

    Article  CAS  Google Scholar 

  47. Walle T. Bioavailability of resveratrol. Ann N Y Acad Sci. 2011;1215:9–15.

    Article  CAS  Google Scholar 

  48. Boocock DJ, Patel KR, Faust GE, Normolle DP, Marczylo TH, Crowell JA, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Anal Technol Biomed Life Sci. 2007;848:182–7.

    Article  CAS  Google Scholar 

  49. Banach M, Aronow WS, Serban C, Sahabkar A, Rysz J, Voroneanu L, et al. Lipids, blood pressure and kidney update 2014. Pharmacol Res. 2015;95-96:111–25.

    Article  CAS  Google Scholar 

  50. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005;49:472–81.

    Article  CAS  Google Scholar 

  51. Andreadi C, Britton RG, Patel KR, Brown K. Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy. 2014;10:524–5.

    Article  Google Scholar 

  52. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica. 2000;30:609–17.

    Article  Google Scholar 

  53. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H, et al. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55:1169–76.

    Article  CAS  Google Scholar 

  54. Ortuño J, Covas MI, Farre M, Pujadas M, Fito M, Khymenets O, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem. 2010;120:1123–30.

    Article  Google Scholar 

  55. Omoya T, Shimizu I, Zhou Y, Okamura Y, Inoue H, Lu G, et al. Effects of idoxifene and estradiol on NF-kappaB activation in cultured rat hepatocytes undergoing oxidative stress. Liver. 2001;21:183–91.

    Article  CAS  Google Scholar 

  56. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319–29.

    Article  CAS  Google Scholar 

  57. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, Su R, et al. Novel insights of dietary polyphenols and obesity. J Nutr Biochem. 2014;25:1–18.

    Article  Google Scholar 

  58. Halle M, Berg A, Northoff H, Keul J. Importance of TNF-alpha and leptin in obesity and insulin resistance: a hypothesis on the impact of physical exercise. Exerc Immunol Rev. 1998;4:77–94.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors are extremely grateful to the data collection team at the Neyshabur University of Medical Sciences.

Financial support

This work was supported by Neyshabur University of Medical Sciences (grant number: 911).

Author information

Authors and Affiliations

  1. Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

    Fahimeh Haghighatdoost

  2. Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

    Fahimeh Haghighatdoost

  3. Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

    Mitra Hariri

Authors
  1. Fahimeh Haghighatdoost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitra Hariri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitra Hariri.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haghighatdoost, F., Hariri, M. Can resveratrol supplement change inflammatory mediators? A systematic review and meta-analysis on randomized clinical trials. Eur J Clin Nutr 73, 345–355 (2019). https://doi.org/10.1038/s41430-018-0253-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41430-018-0253-4

This article is cited by

Search

Advanced search

Quick links